Balofloxacin CAS 127294-70-6

Product Description:

Product Name: Balofloxacin CAS NO: 127294-70-6

Synonyms:

3-Quinolinecarboxylicacid,1-cyclopropyl-6-fluoro-1,4-dihydro-8-M-ethoxy-7-[3-(MethylaMino)-1-piperidinyl]-4-oxo-;

1-Cyclopropyl-6-fluoro-8-M-ethoxy-7-(3-(MethylaMino)piperidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;

Chemical & Physical Properties:

Appearance: Crystalline solid

Assay :≥99.00%

Density: 1.4 g/cm3

Boiling Point: 608.3℃ at 760 mmHg

Melting Point: 137℃

Flash Point: 321.7℃

Refractive Index: 1.639

Storage Condition: Store in original container in a cool dark place.

Vapor Pressure: 1.19E-15mmHg at 25℃

Safety Information:

HS Code: 2933990090

Balofloxacin is quinolone antibiotic, inhibiting the synthesis of bacterial DNA by interference with the enqyme DNA gyrase.Target: Antibacterial; DNA gyrase.Balofloxacin, an orally active fluoroquinolone antibiotic, has been developed by Choongwae Pharma in Korea, for the treatment of urinary tract infection (UTI). Chugai and Ciba were developing balofloxacin for respiratory tract infections (RTI) but discontinued development in 1995 due to changes in Chugai's R&D focus and a lack of efficacy of the drug. Following phase II trials, Choongwae bought the rights to develop balofloxacin in Korea from Chugai. Phase III trials for UTI were completed in early 2001. Balofloxacin was approved by the Korean FDA in December 2001 for UTI. In March 2002, phase II trials were underway for RTI.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.